SCHEMBL902252

SCHEMBL902252

CCOC(=O)c1nc2ccnn2c(O)c1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.46
KCNN3 Q9UGI6 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 4/20 0.43
TRPV1 Q8NER1 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902261 0.88 PDE4A (0.49) PDE4ANPSR1KDM4EALDH1A1HPGD
SCHEMBL902527 0.88 KCNN3 (0.43) KCNN3KMT2AMEN1NPSR1MAPT
SCHEMBL15274729 0.87 PDE4A (0.50) PDE4AKCNN3KMT2AMEN1NPSR1
SCHEMBL902370 0.86 KCNN3 (0.47) KCNN3KMT2AMEN1MAPTTRPV1
SCHEMBL902449 0.85 PDE4A (0.48) PDE4AKCNN3KMT2AMEN1MAPT
SCHEMBL902329 0.81 PDE4A (0.47) PDE4AKMT2ANPSR1MAPTKDM4E
SCHEMBL902676 0.80 PDE4A (0.44) PDE4AMAPTALDH1A1
SCHEMBL902640 0.78 ALDH1A1 (0.52) PDE4AMAPTKDM4EALDH1A1HPGD
SCHEMBL15274731 0.76 KCNN3 (0.41) PDE4AKCNN3KMT2AMEN1NPSR1
SCHEMBL28790830 0.76 PDE4A (0.60) PDE4AKMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PDE4A 1751/4885KCNN3 4658/4885KMT2A 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.